F. Hoffmann-La Roche Ltd (manufacturing of unpackaged products, primary packaging, secondary packaging, quality control testing, batch release)

Ukraine

All drugs from this manufacturer

  • KADSILA

    The drug is indicated for the treatment of adult patients with HER2-positive early breast cancer (following prior taxane and HER2-targeted therapy) or for the treatment of HER2-positive unresectable locally advanced or metastatic breast cancer.

    Dosage form: powder for concentrate for infusion solution

    Active substance Dosage
    trastuzumab emtansine 100 mg

    ATC: L01FD03

  • KADSILA®

    The drug is used for the treatment of adults with HER2-positive early breast cancer (following prior taxane and HER2-targeted therapy) or for the treatment of HER2-positive unresectable locally advanced or metastatic breast cancer.

    Dosage form: powder for concentrate for infusion solution

    Active substance Dosage
    trastuzumab emtansine 160 mg

    ATC: L01FD03